Sign In
Section Navigation
Common Title039
Official Title A Six-Month Safety and Antiviral Study in HIV-1 Seropositive, AZT-Experienced Patients With CD4 Counts Less Than or Equal to 50 Cells/mm3 to Evaluate Indinavir (MK-639) Alone Versus Zidovudine (AZT) and 3TC Versus the Combination of Indinavir (MK-639) With AZT/3TC
Phase Phase III
ClinicalTrials.gov NCT00002155
Treatments
Indinavir
Indinavir Crixivan

Indinavir

Tradename:CrixivanOther Names:IDVClass:Protease Inhibitors (PI)
Categories Treatment-ExperiencedPharmacologyAdverse EffectsDual TherapyMonotherapy
Funding
IndustryMerck Sharp & Dohme Corp
References
  • Hirsch M, Steigbigel R, Staszewski S, et al. A randomized, controlled trial of indinavir, zidovudine, and lamivudine in adults with advanced human immunodeficiency virus type 1 infection and prior antiretroviral therapy. J Infect Dis. 1999;180:659-65.
    [PubMed Abstract]
  • Hirsch MS, Steigbigel RT, Staszewski S, et al. Long-term efficacy, safety, and tolerability of indinavir-based therapy in protease inhibitor-naive adults with advanced HIV infection. Clin Infect Dis. 2003;37:1119-24.
    [PubMed Abstract]

Share by e-mail

Since you've received 80% or better on this quiz, you may claim continuing education credit.

You seem to have a popup blocker enabled. If you want to skip this dialog please Always allow popup windows for the online course.